Alector Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934FOR THE TRANSITION PERIOD FROMTOCommission File Number 001-38792 Alector, Inc. (Exact name of Registrant as specified in its Charter) Not applicable(Former name, former address, and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Exchange Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐Emerging growth company☐ Accelerated filer☒ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 1, 2026, the registrant had 111,025,187 shares of common stock, $0.0001 par value per share, outstanding. Alector, Inc. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations and Comprehensive Loss2Condensed Consolidated Statements of Stockholders’ Equity3Condensed Consolidated Statements of Cash Flows5Notes to Condensed Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations13Item 3.Quantitative and Qualitative Disclosures About Market Risk19Item 4.Controls and Procedures20 PART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historicalfacts contained in this report, including statements regarding our future results of operations and financial position, businessstrategy, product candidates, plans for and results of our research, preclinical studies and clinical trials, research and developmentcosts, regulatory approvals, timing, and likelihood of success, as well as plans and objectives of management for future operations,are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors thatare in some cases beyond our control and may cause our actual results, performance, or achievements to be materially differentfrom any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,”“plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or“continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this report include,but are not limited to, statements about: •our plans relating to the development and manufacturing of our product candidates and research programs;•our plans for advancing research and pre-clinical stage programs into clinical development and our ability to execute onthose plans;•the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;•the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates;•the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators withdevelopment, regulatory and commercialization expertise;•our estimates of the number of